Allogeneic anti-BCMA-CAR T cells PBCAR269A

{
  "id": "MLC-T-ONC-009797",
  "term": "Allogeneic anti-BCMA-CAR T cells PBCAR269A",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of allogeneic, off-the-shelf Tlymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-BCMA-CAR T cells PBCAR269A specifically recognize and kill BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival.",
  "synonyms": [
    "allogeneic anti-BCMA-CAR T lymphocytes PBCAR269A",
    "allogeneic anti-BCMA CAR T cells PBCAR269A"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/allogeneic-anti-bcma-car-t-cells-pbcar269a/"
}